JP2018501287A5 - - Google Patents

Download PDF

Info

Publication number
JP2018501287A5
JP2018501287A5 JP2017536301A JP2017536301A JP2018501287A5 JP 2018501287 A5 JP2018501287 A5 JP 2018501287A5 JP 2017536301 A JP2017536301 A JP 2017536301A JP 2017536301 A JP2017536301 A JP 2017536301A JP 2018501287 A5 JP2018501287 A5 JP 2018501287A5
Authority
JP
Japan
Prior art keywords
group
alkyl
independently selected
heterocyclyl
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017536301A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018501287A (ja
JP6659703B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/012659 external-priority patent/WO2016112298A1/en
Publication of JP2018501287A publication Critical patent/JP2018501287A/ja
Publication of JP2018501287A5 publication Critical patent/JP2018501287A5/ja
Application granted granted Critical
Publication of JP6659703B2 publication Critical patent/JP6659703B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017536301A 2015-01-09 2016-01-08 ピリダジノン誘導体および癌の処置におけるそれらの使用 Expired - Fee Related JP6659703B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562101953P 2015-01-09 2015-01-09
US62/101,953 2015-01-09
PCT/US2016/012659 WO2016112298A1 (en) 2015-01-09 2016-01-08 Pyridazinone derivatives and their use in the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2018501287A JP2018501287A (ja) 2018-01-18
JP2018501287A5 true JP2018501287A5 (enExample) 2019-01-31
JP6659703B2 JP6659703B2 (ja) 2020-03-04

Family

ID=55299747

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017536301A Expired - Fee Related JP6659703B2 (ja) 2015-01-09 2016-01-08 ピリダジノン誘導体および癌の処置におけるそれらの使用

Country Status (5)

Country Link
US (1) US10239861B2 (enExample)
EP (1) EP3242874B1 (enExample)
JP (1) JP6659703B2 (enExample)
CN (1) CN107406429B (enExample)
WO (1) WO2016112298A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107074824B (zh) 2014-09-05 2021-01-08 基因泰克公司 作为用于治疗癌症的pcaf和gcn5抑制剂的式(i)的酞嗪衍生物
JP6814730B2 (ja) 2014-09-05 2021-01-20 ジェネンテック， インコーポレイテッド 治療用化合物およびその使用
KR102194536B1 (ko) * 2019-06-10 2020-12-23 연세대학교 산학협력단 타목시펜의 반응성 예측용 조성물
CN112824381B (zh) * 2019-11-21 2024-04-26 广东东阳光药业股份有限公司 一种哌啶胺的制备方法
BR112022024729A2 (pt) 2020-06-05 2023-02-28 Kinnate Biopharma Inc Inibidores de quinases do receptor do fator de crescimento de fibroblastos
WO2022076735A1 (en) * 2020-10-09 2022-04-14 Regents Of The University Of Minnesota Inhibitors of the bromodomain phd finger transcription factor (bptf) as anti-cancer agents
KR102766287B1 (ko) * 2021-10-15 2025-02-12 고려대학교 산학협력단 피리다벤을 포함하는 자궁내막 세포, 영양막 세포 또는 고환 세포의 비정상적 증식 관련 질환의 예방 또는 치료용 약학적 조성물
AU2023333181A1 (en) 2022-09-02 2025-03-13 Auron Therapeutics, Inc. Pyridazinon derivatives as kat2 degraders for the treatment of proliferative disorders

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
AU639726B2 (en) 1989-09-08 1993-08-05 Duke University Structural alterations of the egf receptor gene in human gliomas
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
FR2707294B1 (fr) 1993-07-06 1995-09-29 Pf Medicament Nouveaux dérivés de la 3,5-dioxo-(2H,4H)-1,2,4-triazine, leur préparation et leur application en thérapeutique humaine.
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
EP0659439B1 (en) 1993-12-24 2001-10-24 MERCK PATENT GmbH Immunoconjugates
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
CN1068323C (zh) 1994-07-21 2001-07-11 阿克佐诺贝尔公司 环酮过氧化物配制剂
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
DE69522717T2 (de) 1995-03-30 2002-02-14 Pfizer Inc., New York Chinazolinderivate
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
EP0831880A4 (en) 1995-06-07 2004-12-01 Imclone Systems Inc ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH
ATE212993T1 (de) 1995-07-06 2002-02-15 Novartis Erfind Verwalt Gmbh Pyrolopyrimidine und verfahren zu ihrer herstellung
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
HU228446B1 (en) 1996-04-12 2013-03-28 Warner Lambert Co Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof
JP4386967B2 (ja) 1996-07-13 2009-12-16 グラクソ、グループ、リミテッド プロテインチロシンキナーゼ阻害剤としての縮合複素環式化合物
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EP0980244B1 (en) 1997-05-06 2003-06-04 Wyeth Holdings Corporation Use of quinazoline compounds for the treatment of polycystic kidney disease
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
KR20010031813A (ko) 1997-11-06 2001-04-16 윌리암 에이취 캘넌, 에곤 이 버그 결장 폴립 치료용 티로신 키나제 억제제로서의 퀴나졸린유도체의 용도
EP1131304B1 (en) 1998-11-19 2002-12-04 Warner-Lambert Company N- 4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
CN1905873A (zh) * 2003-11-19 2007-01-31 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
ES2563954T3 (es) 2004-06-30 2016-03-16 Janssen Pharmaceutica Nv Derivados de ftalazina como inhibidores de PARP
JP2012131708A (ja) * 2009-04-28 2012-07-12 Nissan Chem Ind Ltd ４位置換ピリダジノン化合物及びｐ２ｘ７受容体阻害剤
EP2576520A1 (en) 2010-05-28 2013-04-10 GE Healthcare UK Limited Radiolabeled compounds and methods thereof
UY35103A (es) 2012-10-29 2014-05-30 Glaxo Group Ltd Compuestos de cefem 2-sustituidos
WO2014096965A2 (en) * 2012-12-21 2014-06-26 Rvx Therapeutics Inc. Novel heterocyclic compounds as bromodomain inhibitors
US9200005B2 (en) 2013-03-13 2015-12-01 AbbVie Deutschland GmbH & Co. KG Inhibitor compounds of phosphodiesterase type 10A
CA2906100A1 (en) * 2013-03-15 2014-09-18 Genentech, Inc. Treating th2-mediated diseases by inhibition of bromodomains
CN107074824B (zh) 2014-09-05 2021-01-08 基因泰克公司 作为用于治疗癌症的pcaf和gcn5抑制剂的式(i)的酞嗪衍生物
JP6814730B2 (ja) 2014-09-05 2021-01-20 ジェネンテック， インコーポレイテッド 治療用化合物およびその使用

Similar Documents

Publication Publication Date Title
JP2018501287A5 (enExample)
JP2019516757A5 (enExample)
JP2017530176A5 (enExample)
JP2017533250A5 (enExample)
JP2017526696A5 (enExample)
JP2019516759A5 (enExample)
JP2017533249A5 (enExample)
JP2017537100A5 (enExample)
JP2018510851A5 (enExample)
JP2017533248A5 (enExample)
JP2017525740A5 (enExample)
JP2017530984A5 (enExample)
JP2018505169A5 (enExample)
RU2018138828A (ru) Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами
CN107250149A (zh) 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物
JP2012510990A5 (enExample)
JP2019529444A5 (enExample)
JP2019510832A5 (enExample)
JP2013510123A5 (enExample)
JP2016506916A5 (enExample)
JP2016529312A5 (enExample)
JP2015500209A5 (enExample)
JP2017510641A5 (enExample)
HRP20171154T1 (hr) Kristalni inhibitori bromodomene
JP2018529742A5 (enExample)